Equities

Qingdao Vland Biotech INC

603739:SHH

Qingdao Vland Biotech INC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)10.34
  • Today's Change-0.14 / -1.34%
  • Shares traded2.96m
  • 1 Year change-26.46%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments514420482
Total Receivables, Net366346296
Total Inventory205174157
Prepaid expenses211629
Other current assets, total18147.82
Total current assets1,124969972
Property, plant & equipment, net1,5761,3391,056
Goodwill, net842020
Intangibles, net140136131
Long term investments76778.59
Note receivable - long term5.00----
Other long term assets------
Total assets3,0342,5792,222
LIABILITIES
Accounts payable226141112
Accrued expenses927546
Notes payable/short-term debt596396150
Current portion long-term debt/capital leases93--1.00
Other current liabilities, total823364
Total current liabilities1,088645372
Total long term debt6214999
Total debt751545250
Deferred income tax3.022.722.88
Minority interest1178981
Other liabilities, total554862
Total liabilities1,326934617
SHAREHOLDERS EQUITY
Common stock253252252
Additional paid-in capital712705694
Retained earnings (accumulated deficit)760704675
Treasury stock - common------
Unrealized gain (loss)(16)(17)--
Other equity, total(0.1)(0.11)(16)
Total equity1,7081,6451,605
Total liabilities & shareholders' equity3,0342,5792,222
Total common shares outstanding253252252
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.